Tardive dyskinesia and atypical antipsychotic drugs

  title={Tardive dyskinesia and atypical antipsychotic drugs},
  author={Daniel E. Casey},
  journal={Schizophrenia Research},
  • D. Casey
  • Published 1 March 1999
  • Psychology, Medicine
  • Schizophrenia Research

Tardive dyskinesia in elderly patients: an update.

  • R. Goldberg
  • Psychology, Medicine
    Journal of the American Medical Directors Association
  • 2003

Extrapyramidal Symptoms with Atypical Antipsychotics

The use of atypical antipsychotics as first line therapy for the treatment of schizophrenia is based largely on their reduced risk of EPS compared with conventional antipsychotic medications, Nevertheless, EPS with these drugs can occur, particularly when prescribed at high doses.

Untitled Page

Frequent monitoring, while noting a patient’s subjective experience, remains the best strategy for choosing therapy to maximize symptom relief and minimize the impact of EPS and other side effects over the longterm.

Tardive Dyskinesia: Treatment with Aripiprazole

  • N. KangMoon-Doo Kim
  • Psychology, Medicine
    Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2011
Aripiprazole has a unique mechanism of action and has various effects in tardive dyskinesia, and the drug acts as a partial D2 receptor agonist that can stabilize D2 up-regulation and a 5-HT2A receptor antagonist that can increase the release of dopamine in the striatum.

Implications of the CATIE Trial on Treatment: Extrapyramidal Symptoms

  • D. Casey
  • Psychology, Medicine
    CNS Spectrums
  • 2006
The reported results of the CATIE trial regarding EPS are explored and the differentiation of the atypicals from perphenazine on EPS is emphasized and how these results should be incorporated into daily practice for the clinician is emphasized.

Historical perspectives on tardive dyskinesia

Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia.

Data from six trials showed that there may be a clinically important improvement in TD symptoms after GABA agonist treatment compared with placebo at six to eight weeks follow-up, and the risk of bias in the included studies was unclear.

Investigating a novel antioxidant approach to the treatment of tardive dyskinesia

The purpose of the current study was to establish a valid animal model of TD, followed by the evaluation of the behavioural and neurochemical effects of chronic NAC administration at various doses in a nonpathological state, i.e. in healthy rats.



Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia.

The pressing need is for novel compounds which treat schizophrenia and are free of the undesirable motor system effects (a nonneuroleptic neuroleptic).

Tardive dyskinesia and diabetes mellitus.

Possible pathophysiologic mechanisms for the increased prevalence of tardive dyskinesia in neuroleptic-treated patients with diabetes will be discussed.

Will the new antipsychotics bring hope of reducing the risk of developing extrapyramidal syndromes and tardive dyskinesia?

  • D. Casey
  • Psychology, Medicine
    International clinical psychopharmacology
  • 1997
The advent of new agents such as sertindole, olanzapine and seroquel seems likely to fulfill the promise that it is possible to have antipsychotic agents with a low EPS liability, and possibly a low risk of tardive dyskinesia.

Tardive dyskinesia in older out‐patients: a follow‐up study

Although TD was common, it rarely progressed in this naturalistic setting, suggesting that even for older patients maintenance neuroleptic treatment may be feasible for chronic psychosis.

The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.

Neuroleptic-treated diabetics had a significantly higher prevalence and severity of tardive dyskinesia, and it is suggested that diabetes mellitus should be examined further as a risk factor for tardiv dysKinesia.

The differential diagnosis of tardive dyskinesia

  • D. Casey
  • Psychology, Medicine
    Acta psychiatrica Scandinavica. Supplementum
  • 1981
A thorough history, including past and present drug use, and a complete physical, neurological, and psychiatric examination, accompanied by appropriate laboratory tests, are often necessary to make the correct differential diagnosis of dyskinesias.

Prospective study of tardive dyskinesia incidence in the elderly.

Investigation of the incidence of tardive dyskinesia in elderly individuals beginning treatment with antipsychotic drugs found psychiatric (as opposed to organic) diagnosis and presence of extrapyramidal signs early in treatment were associated with increased tardiv dyskine vulnerability.

Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life.

Within elderly populations, duration of exposure to neuroleptics is the strongest predictor of risk for tardive dyskinesia, and this risk increases rapidly within the first year of total lifetime neuroleptic use.

Tardive dyskinesia: a 3-year follow-up study

The amount of purposeless trunk and limb movement present proved to be a relatively stable phenomenon, showing only a slight increase with age and no change over the follow-up period.

Effects of Risperidone in Tardive Dyskinesia: An Analysis of the Canadian Multicenter Risperidone Study*

  • G. Chouinard
  • Psychology, Medicine
    Journal of clinical psychopharmacology
  • 1995
Risperidone at 6 mg/day had the most beneficial effect on TD, especially on the BLM syndrome, without inducing significant parkinsonism while treating psychotic symptoms, and was greater than with either placebo or haloperidol.